ClinicalTrials.gg
CompletedNCT01480596Updated Feb 9, 2017Results posted

The Evaluation of Belimumab in Myasthenia Gravis (MG)

A Phase 2 interventional study of Belimumab and Placebo in Myasthaenia Gravis, sponsored by GlaxoSmithKline. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Study BEL115123 is a randomized, placebo-controlled, double-blind, multinational study of belimumab (10 mg/kg) to investigate the efficacy and safety of belimumab in subjects with MG. The study will enroll male and female outpatients (> or equal to 18 years of age) with a diagnosis of MG who are 1) acetylcholine receptor (AChR) antibody positive or muscle specific kinase (MuSK) antibody positive, 2) on current standard of care therapy, and 3) continue to exhibit signs of MG. The study will include 3 phases: a 4 week screening period, a 24 week treatment period, and a 12 week follow-up period. IP will be administered intravenously on Days 0, 14, 28 and then every 28 days through and including Week 20. At Week 24, primary outcomes will be obtained. Follow up evaluations will be conducted at Weeks 28, 32 and 36 for all subjects. The primary objective of this study is to assess the efficacy of belimumab as evaluated by the change in the quantitative myasthenia gravis (QMG) score.

02

Conditions studied

  • Myasthaenia Gravis
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older, with of greater than 1 year.
  • MG of class II to IVa inclusive.
  • Acetylcholine receptor (AChR) or muscle specific kinase (MuSK) antibody positive.
  • Stable dose (defined as no dose changes) not exceeding the maximum doses given in Section 5.6.1 of the following therapy(ies) prior to screening: Cholinesterase inhibitor(pyridostigmine or equivalent) for at least 2 weeks prior to screening and no ; Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to screening and/or only one of the following: prednisone (up to 40 mg/day or equivalent) for at least 1 month prior to screening; azathioprine for at least 6 months prior to screening; mycophenolate for at least 6 months prior to screening, or cyclosporine for at least 3 months prior to screening; or Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to screening and/or prednisone (up to 20 mg/day or equivalent) for at least 1 month prior to screening and only one of the following: azathioprine for at least 6 months prior to screening, mycophenolate for at least 6 months prior to screening, or cyclosporine for at least 3 months prior to screening
  • Quantitative Myasthenia Gravis (QMG) score of 8 or greater, with at least 4 points derived from signs other than ocular
  • A female subject is eligible to participate if she is: Of non-; Of childbearing potential and NOT pregnant or nursing, has a negative serum pregnancy test at screening, and agrees to one of the following: Complete abstinence from penile-vaginal intercourse, when this is the female's preferred and usual lifestyle, for the period from consent into the study until 16 weeks after the last dose of product; or Consistent and correct use of one of the following acceptable methods of for the period from consent into the study until 16 weeks after the last dose of investigational product: Oral contraceptives (either combined or progesterone only), Injectable progesterone, Implants of etonogestrel or levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year, Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study; this male must be the sole partner for the subject, Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
  • Capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form.
  • Single less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch Block.
  • and ALT less than 2xULN; alkaline phosphatase and less or = to 1.5xULN (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).

Exclusion criteria

Exclusion Criteria:

  • Participated in a clinical trial and has received an product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) prior to screening or planning to take any investigational drug for the planned duration of study participation (6 months after the last dose of study drug).
  • Presence or previous history of thymoma.
  • Thymectomy within 12 months
  • (in the opinion of investigator) abnormal laboratory values.
  • Pregnant females as determined by positive (serum) hCG test at screening or prior to dosing, or lactating females or planning to become pregnant within 16 weeks after last dose of investigational product.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • May require (in the opinion of investigator) treatment with IVIg and/or plasmapheresis during the 24 week treatment period.
  • Have received IVIg and/or plasmapheresis within 90 days prior to screening.
  • Have received any other biopharmaceutical agent (except IVIg as described in exclusion criteria #8) in the 364 days prior to screening.
  • Have received treatment with any B cell targeted therapy (e.g., rituximab, belimumab), at any time.
  • Have received a within 30 days of study Day 0 (baseline).
  • Have received cyclophosphamide or any other agent apart from the ones allowed by the inclusion criteria #4, within the past 6 months.
  • Have another medical condition that requires treatment with or immunosuppressive agents.
  • Hospitalization due to infection or use of parenteral antibacterial, antifungal or antiviral agents within 60 days prior to screening; or history of recurrent or chronic infection, or currently active systemic infection.
  • Have a history of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
  • Have a history of a major organ transplant (eg, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
  • Have a historically positive test or test positive at screening for -1, surface antigen or antibody.
  • Have an IgG Grade 3 or greater deficiency (less than or = to 400mg/dL).
  • Have an IgA deficiency (IgA less than 10mg/dL).
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • Has a progressive medical, neurological or psychological condition or situation that, in the investigator's judgment, is likely to cause the subject to be unable or unwilling to participate in study procedures, to complete all scheduled assessments, or precludes accurate assessments.
  • Is currently abusing drugs or alcohol or has history of abuse in the last 12 months.
  • Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Belimumab

    10mg/kg

    Biological: Belimumab

  • Placebo comparator
    Placebo

    placebo IV infusion

    Other: Placebo

Interventions

  • BiologicalBelimumab

    10mg/kg IV infusion

  • OtherPlacebo

    placebo IV infusion

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24

    The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means were presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline QMG Score, Treatment by Visit, and Baseline QMG Score by Visit.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Number of Participants With Improvement by Greater Than or Equal to (>=) 3 Points From Baseline Through to Week 24 in the QMG Score

    The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Proportions compared using exact analyses stratified by the observed median Baseline score (less than or equal to \[\<=\] median, greater than \[ \>\] median). Exact odds ratio, double the exact one-sided p-value and exact confidence intervals were presented. Participants with missing data were assumed to have a negative response.

    Time frame: Baseline and up to Week 24

  2. Number of Participants Worsening by >=3 Points in QMG Score From Baseline Through to Week 24

    The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Proportions compared using exact analyses stratified by the observed median Baseline score (\<=median, \> median). Exact odds ratio, double the exact one-sided p-value and exact confidence interval were presented. Participants with missing data were assumed to have a worsening response.

    Time frame: Baseline and up to Week 24

  3. Number of Participants With a Sustained Response in the QMG Score

    A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Odds ratios are calculated by Cochran-Mantel-Haenszel method stratified by the observed median baseline score (\<= median, \> median). Wald confidence intervals and p-values were presented.

    Time frame: Baseline and up to Week 24

  4. Median Time to QMG Response Which is Sustained From Earliest Time Point at Which Improvement by >=3 Points From Baseline is Observed and Maintained Through Week 24

    A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores.

    Time frame: Baseline and up to Week 24

  5. Mean Change From Baseline for QMG Score at Week 28, Week 32 and Week 36

    The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. Total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (mild) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at baseline (BL) is the average of the screening and Week 0 BL scores. Change from BL was calculated by subtracting the BL value from the post-BL value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative trt difference indicates benefit relative to placebo. Analysis method was Mixed-Model Repeated Measures adjusted for Trt, Visit, BL QMG Score, Trt by Visit and BL QMG Score by Visit. Only follow-up visits are presented but the analysis also includes all trt phase visits. Only those par. available at indicated time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, Week 28, Week 32 and Week 36

  6. Mean Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Through to Week 24

    The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MGC Score, Treatment by Visit, and Baseline MGC Score by Visit.

    Time frame: Baseline and up to Week 24

  7. Number of Participants With Improvement by >=3 Points From Baseline Through to Week 24 in the MGC Score

    The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Proportions compared using exact analyses stratified by the observed median baseline score (\<= median, \> median). Exact odds ratios, double the exact one-sided p-values and exact confidence intervals were presented. Participants with missing data were assumed to have a negative response.

    Time frame: Baseline and up to Week 24

  8. Number of Participants Worsening by >=3 Points From Baseline Through to Week 24 in the MGC Score

    The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Proportions compared using exact analyses stratified by the observed median baseline score (\<= median, \> median). Exact odds ratios, double the exact one-sided p-values and exact confidence intervals were presented. Participants with missing data were assumed to have a worsening response.

    Time frame: Baseline and up to Week 24

  9. Number of Participants With a Sustained Response in the MGC Score

    AA sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Odds ratios are calculated by Cochran-Mantel-Haenszel method without adjusting for any strata. Wald confidence intervals and p-values were presented.

    Time frame: Baseline and up to Week 24

  10. Median Time to MGC Response Which is Sustained From Earliest Time Point at Which Improvement by >=3 Points From Baseline is Observed and Maintained Through Week 24

    A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants' last available assessment prior to initiation of study intravenous (IV) infusion.

    Time frame: Baseline and up to Week 24

  11. Mean Change From Baseline for MGC Score at Week 28, Week 32 and Week 36

    The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participant's last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-BL value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MGC Score, Treatment by Visit, and Baseline MGC Score by Visit. Only follow-up visits are presented but the analysis also includes all treatment phase visits. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, Week 28, Week 32 and Week 36

  12. Number of Participants With a Myasthenia Foundation of America-post Intervention Status (MGFA-PIS) of Minimal Manifestation or Better at Week 24 and Week 36.

    Myasthenia Foundation of America-post intervention status assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

    Time frame: Week 24 and Week 36

  13. Number of Participants With MGFA-PIS of Pharmacologic Remission or Better at Week 24 and Week 36

    Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

    Time frame: Week 24 and Week 36

  14. Number of Participants With MGFA-PIS of Minimal Manifestation Sustained Response (MM at Week 12 and Maintained the Response Through Week 24)

    Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

    Time frame: Week 12 through Week 24

  15. Number of Participants With MGFA-PIS of Pharmacologic Response Sustained Response (PR at Week 12 and Maintained the Response Through Week 24)

    Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

    Time frame: Week 12 through Week 24

  16. Number of Participants With MGFA-PIS (Unchanged, Improved, Worsened) at Week 24 and Week 36

    Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being unchanged, improved or worsened.

    Time frame: Week 24 and Week 36

  17. Mean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 12 and Week 24

    The total MG-ADL score was calculated by adding the score of each of the 8 individual MG-ADL questions. Possible total MG-ADL scores ranges from 0 (normal) to 24 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MG-ADL Score, Treatment by Visit, and Baseline MG-ADL Score by Visit. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, Week 12 and Week 24

  18. Mean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 28, Week 32 and Week 36

    The total MG-ADL score was calculated by adding the score of each of the 8 individual MG-ADL questions. Possible total MG-ADL scores range from 0 (normal) to 24 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participant's last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-Baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MG-ADL Score, Treatment by Visit, and Baseline MG-ADL Score by Visit. Only follow-up visits are presented but the analysis also includes all treatment phase visits. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline, Week 28, Week 32 and Week 36

07

Results

Posted Apr 27, 2016

Participant flow

Participants (par.) with myasthenia gravis (MG) and who were acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody positive, on current standard of care therapy and continued to exhibit signs of MG were eligible for participation in the study.

Participant flow — Overall Study
MilestonePlacebo IVBelimumab 10 mg/kg IV
Started2218
Completed1716
Not completed52
Withdrew: Adverse event30
Withdrew: Mg exacerbation or change in medication22

Outcome measures

PrimaryMean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24

The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means were presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline QMG Score, Treatment by Visit, and Baseline QMG Score by Visit.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24-2.37 ± 1.099-4.21 ± 1.143
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.256 · Mean difference (final values): -1.84 · 95% CI -5.08 to 1.40Standard error of mean is for adjusted difference.
SecondaryNumber of Participants With Improvement by Greater Than or Equal to (>=) 3 Points From Baseline Through to Week 24 in the QMG Score

The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Proportions compared using exact analyses stratified by the observed median Baseline score (less than or equal to \[\<=\] median, greater than \[ \>\] median). Exact odds ratio, double the exact one-sided p-value and exact confidence intervals were presented. Participants with missing data were assumed to have a negative response.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants With Improvement by Greater Than or Equal to (>=) 3 Points From Baseline Through to Week 24 in the QMG Score
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants With Improvement by Greater Than or Equal to (>=) 3 Points From Baseline Through to Week 24 in the QMG Score611
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · exact methods · p = 0.082 · Odds ratio (or): 3.81 · 95% CI 0.87 to 19.02
SecondaryNumber of Participants Worsening by >=3 Points in QMG Score From Baseline Through to Week 24

The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Proportions compared using exact analyses stratified by the observed median Baseline score (\<=median, \> median). Exact odds ratio, double the exact one-sided p-value and exact confidence interval were presented. Participants with missing data were assumed to have a worsening response.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants Worsening by >=3 Points in QMG Score From Baseline Through to Week 24
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants Worsening by >=3 Points in QMG Score From Baseline Through to Week 2442
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · exact methods · p = 0.827 · Odds ratio (or): 0.55 · 95% CI 0.05 to 4.35
SecondaryNumber of Participants With a Sustained Response in the QMG Score

A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores. Odds ratios are calculated by Cochran-Mantel-Haenszel method stratified by the observed median baseline score (\<= median, \> median). Wald confidence intervals and p-values were presented.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants With a Sustained Response in the QMG Score
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants With a Sustained Response in the QMG Score58
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Cochran-Mantel-Haenszel · p = 0.184 · Odds ratio (or): 2.51 · 95% CI 0.62 to 10.10
SecondaryMedian Time to QMG Response Which is Sustained From Earliest Time Point at Which Improvement by >=3 Points From Baseline is Observed and Maintained Through Week 24

A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. The total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (normal) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at Baseline is the average of the screening and Week 0 Baseline scores.

Time frame:
Baseline and up to Week 24

No measurements were reported for this outcome.

SecondaryMean Change From Baseline for QMG Score at Week 28, Week 32 and Week 36

The QMG is a 13 item ordinal scale which measures ocular, bulbar, extremity fatigue and strength, along with respiratory function. Total QMG score was calculated by adding the score of each of the 13 individual QMG questions. Possible scoring on the QMG range from 0 (mild) to 39 (severe). A lower score indicates a better clinical outcome. The QMG score at baseline (BL) is the average of the screening and Week 0 BL scores. Change from BL was calculated by subtracting the BL value from the post-BL value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative trt difference indicates benefit relative to placebo. Analysis method was Mixed-Model Repeated Measures adjusted for Trt, Visit, BL QMG Score, Trt by Visit and BL QMG Score by Visit. Only follow-up visits are presented but the analysis also includes all trt phase visits. Only those par. available at indicated time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, Week 28, Week 32 and Week 36
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline for QMG Score at Week 28, Week 32 and Week 36
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Week 28, n=16, 14-3.33 ± 0.839-5.03 ± 0.889
Week 32, n=15, 16-2.82 ± 0.880-4.12 ± 0.904
Week 36, n=17, 14-2.44 ± 0.872-4.73 ± 0.921
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.175 · Mean difference (final values): -1.70 · 95% CI -4.20 to 0.80Analysis for Week 28. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.310 · Median difference (final values): -1.31 · 95% CI -3.89 to 1.28Analysis for Week 32. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.081 · Median difference (final values): -2.29 · 95% CI -4.88 to 0.30Analysis for Week 36. Standard error of mean is for adjusted difference.
SecondaryMean Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Through to Week 24

The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MGC Score, Treatment by Visit, and Baseline MGC Score by Visit.

Time frame:
Baseline and up to Week 24
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Through to Week 24
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Mean Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Through to Week 24-3.86 ± 1.037-3.81 ± 1.064
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.972 · Mean difference (final values): 0.05 · 95% CI -2.97 to 3.07Standard error of mean is for adjusted difference.
SecondaryNumber of Participants With Improvement by >=3 Points From Baseline Through to Week 24 in the MGC Score

The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Proportions compared using exact analyses stratified by the observed median baseline score (\<= median, \> median). Exact odds ratios, double the exact one-sided p-values and exact confidence intervals were presented. Participants with missing data were assumed to have a negative response.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants With Improvement by >=3 Points From Baseline Through to Week 24 in the MGC Score
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants With Improvement by >=3 Points From Baseline Through to Week 24 in the MGC Score109
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · exact methods · p = 1.000 · Odds ratio (or): 1.17 · 95% CI 0.26 to 5.48
SecondaryNumber of Participants Worsening by >=3 Points From Baseline Through to Week 24 in the MGC Score

The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Proportions compared using exact analyses stratified by the observed median baseline score (\<= median, \> median). Exact odds ratios, double the exact one-sided p-values and exact confidence intervals were presented. Participants with missing data were assumed to have a worsening response.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants Worsening by >=3 Points From Baseline Through to Week 24 in the MGC Score
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants Worsening by >=3 Points From Baseline Through to Week 24 in the MGC Score52
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · exact methods · p = 0.530 · Odds ratio (or): 0.40 · 95% CI 0.03 to 2.89
SecondaryNumber of Participants With a Sustained Response in the MGC Score

AA sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Odds ratios are calculated by Cochran-Mantel-Haenszel method without adjusting for any strata. Wald confidence intervals and p-values were presented.

Time frame:
Baseline and up to Week 24
Reported as:
Number · Number of participants
Number of Participants With a Sustained Response in the MGC Score
Number of participantsPlacebo IVBelimumab 10 mg/kg IV
Number of Participants With a Sustained Response in the MGC Score47
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Cochran-Mantel-Haenszel · p = 0.175 · Odds ratio (or): 2.70 · 95% CI 0.64 to 11.46
SecondaryMedian Time to MGC Response Which is Sustained From Earliest Time Point at Which Improvement by >=3 Points From Baseline is Observed and Maintained Through Week 24

A sustained response during the treatment phase is when a participant improves by \>=3 points from Baseline at Week 12, and the participant maintains at least a 3 point improvement from Baseline through Week 24. The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants' last available assessment prior to initiation of study intravenous (IV) infusion.

Time frame:
Baseline and up to Week 24

No measurements were reported for this outcome.

SecondaryMean Change From Baseline for MGC Score at Week 28, Week 32 and Week 36

The total MGC score was calculated by adding the score of each of the 10 individual MGC questions. Possible total MGC scores range from 0 (normal) to 50 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participant's last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-BL value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MGC Score, Treatment by Visit, and Baseline MGC Score by Visit. Only follow-up visits are presented but the analysis also includes all treatment phase visits. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, Week 28, Week 32 and Week 36
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline for MGC Score at Week 28, Week 32 and Week 36
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Week 28, n=16, 14-4.63 ± 0.856-5.64 ± 0.905
Week 32, n=15, 16-5.46 ± 0.975-5.44 ± 0.948
Week 36, n=17, 14-4.77 ± 0.970-5.04 ± 1.052
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.423 · Mean difference (final values): -1.01 · 95% CI -3.56 to 1.53Analysis for Week 28. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.986 · Mean difference (final values): 0.02 · 95% CI -2.76 to 2.80Analysis for Week 32. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.848 · Mean difference (final values): -0.28 · 95% CI -3.21 to 2.65Analysis for Week 36. Standard error of mean is for adjusted difference.
SecondaryNumber of Participants With a Myasthenia Foundation of America-post Intervention Status (MGFA-PIS) of Minimal Manifestation or Better at Week 24 and Week 36.

Myasthenia Foundation of America-post intervention status assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

Time frame:
Week 24 and Week 36

No measurements were reported for this outcome.

SecondaryNumber of Participants With MGFA-PIS of Pharmacologic Remission or Better at Week 24 and Week 36

Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

Time frame:
Week 24 and Week 36

No measurements were reported for this outcome.

SecondaryNumber of Participants With MGFA-PIS of Minimal Manifestation Sustained Response (MM at Week 12 and Maintained the Response Through Week 24)

Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

Time frame:
Week 12 through Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With MGFA-PIS of Pharmacologic Response Sustained Response (PR at Week 12 and Maintained the Response Through Week 24)

Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being in a status of Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). Only MM and PR were assessed in this study as CR is not achievable based on the definition.

Time frame:
Week 12 through Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With MGFA-PIS (Unchanged, Improved, Worsened) at Week 24 and Week 36

Myasthenia Foundation of America (MGFA) post intervention status (PIS) assesses whether subjects can be categorized as being unchanged, improved or worsened.

Time frame:
Week 24 and Week 36

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 12 and Week 24

The total MG-ADL score was calculated by adding the score of each of the 8 individual MG-ADL questions. Possible total MG-ADL scores ranges from 0 (normal) to 24 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participants last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MG-ADL Score, Treatment by Visit, and Baseline MG-ADL Score by Visit. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 12 and Week 24
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Week 12, n=19, 18-1.33 ± 0.489-1.83 ± 0.511
Week 24, n=17, 17-2.01 ± 0.589-2.32 ± 0.603
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.483 · Mean difference (final values): -0.50 · 95% CI -1.94 to 0.93Statistical analysis is presented for Week 12. Standard error of mean is for adjusted mean difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.711 · Mean difference (final values): -0.31 · 95% CI -2.03 to 1.40Statistical analysis is presented for Week 24. Standard error of mean is for adjusted mean difference.
SecondaryMean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 28, Week 32 and Week 36

The total MG-ADL score was calculated by adding the score of each of the 8 individual MG-ADL questions. Possible total MG-ADL scores range from 0 (normal) to 24 (severe). A lower score indicates a better clinical outcome. Baseline is defined as the participant's last available assessment prior to initiation of study IV infusion. Change from Baseline was calculated by subtracting the Baseline value from the post-Baseline value. The differences in adjusted least square means are presented (Belimumab 10 mg/kg minus Placebo). A negative treatment difference indicates benefit relative to placebo. The analysis method was Mixed-Model Repeated Measures adjusted for Treatment, Visit, Baseline MG-ADL Score, Treatment by Visit, and Baseline MG-ADL Score by Visit. Only follow-up visits are presented but the analysis also includes all treatment phase visits. Only those participants available at the indicated time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline, Week 28, Week 32 and Week 36
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) at Week 28, Week 32 and Week 36
Units on a scalePlacebo IVBelimumab 10 mg/kg IV
Week 28, n=16, 14-1.21 ± 0.522-2.96 ± 0.546
Week 32, n=15, 16-1.52 ± 0.632-1.80 ± 0.619
Week 36, n=17, 14-1.51 ± 0.621-1.78 ± 0.663
Statistical analysis
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.028 · Mean difference (final values): -1.75 · 95% CI -3.30 to -0.20Analysis for Week 28. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.756 · Mean difference (final values): -0.28 · 95% CI -2.10 to 1.55Analysis for Week 32. Standard error of mean is for adjusted difference.
  • Placebo IV vs Belimumab 10 mg/kg IV · Mixed Models Analysis · p = 0.775 · Mean difference (final values): -0.26 · 95% CI -2.12 to 1.59Analysis for Week 36. Standard error of mean is for adjusted difference.

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious AEs were collected from the date first infusion of investigational product up to the Week 24 visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV—4/22 (18.2%)16/22 (72.7%)
Belimumab 10 mg/kg IV—0/18 (0%)14/18 (77.8%)
Most frequent serious events
Most frequent serious events
EventPlacebo IVBelimumab 10 mg/kg IV
CholelithiasisHepatobiliary disorders1/220/18
SepsisInfections and infestations1/220/18
Myasthenia gravisNervous system disorders1/220/18
NephrolithiasisRenal and urinary disorders1/220/18
Aortic dissection ruptureVascular disorders1/220/18
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPlacebo IVBelimumab 10 mg/kg IV
DiarrhoeaGastrointestinal disorders4/221/18
InfluenzaInfections and infestations0/223/18
NauseaGastrointestinal disorders0/223/18
Back painMusculoskeletal and connective tissue disorders3/220/18
HeadacheNervous system disorders3/221/18
Upper respiratory tract infectionInfections and infestations1/222/18
Musculoskeletal painMusculoskeletal and connective tissue disorders2/222/18
PyrexiaGeneral disorders1/222/18
NasopharyngitisInfections and infestations2/221/18
CystitisInfections and infestations2/220/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo IVBelimumab 10 mg/kg IVTotal
Mean59.0 ± 13.8852.7 ± 17.3256.1 ± 15.67
Gender
Gender(Participants)Placebo IVBelimumab 10 mg/kg IVTotal
Female141024
Male7815
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo IVBelimumab 10 mg/kg IVTotal
American Indian or Alaskan Native101
Asian - East Asian Heritage112
White - White/Caucasian/European Heritage191736
08

Study locations

25 sites
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033-0859, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Burlington, Vermont 05405, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6T 2B5, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Tuebingen, Baden-Wuerttemberg 72076, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50924, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Roma, Lazio 00185, Italy
  • GSK Investigational Site
    Milano, Lombardia 20133, Italy
09

References and documents

Publications

  • Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21. PubMed 29661905 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Aug 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Nov 29, 2011
Start
Apr 2013
Primary completionActual
Aug 2015
CompletionActual
Oct 2015
Results first posted
Apr 27, 2016
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01480596
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 29, 2011
Start date
Apr 2013
Primary completion
Aug 2015
Completion
Oct 2015
Results posted
Apr 27, 2016
Last update
Feb 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion